News & Updates
Filter by Specialty:
Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis
24 Dec 2023
byStephen Padilla
Fedratinib is superior to the best available therapy (BAT) in terms of spleen volume reduction (SVR) and symptom response rates in patients with myelofibrosis (MF) treated with the Janus kinase inhibitor (JAKi) ruxolitinib, as shown in a study presented at ASH 2023.
Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis
24 Dec 2023Low-dose naltrexone in fibromyalgia: No pain relief, but memory boost possible
22 Dec 2023
In the treatment of individuals with fibromyalgia, low-dose naltrexone does not appear to help reduce pain but might improve memory instead, as reported in a study.